Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resimmune Phase II in Cutaneous T-Cell Lymphoma
NCT00611208Phase 2Completed
- Sponsor
- Angimmune LLC
- Start
- Jan 2008
- Primary completion
- Feb 2015
- Modality
- Immunotoxins, Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of A-dmDT390-bisFv(UCHT1) in cutaneous T-cell lymphoma (CTCL), sponsored by Angimmune LLC. Primary endpoint: Remission status (complete, partial, stable disease, progressive disease) at 6 years. Started Jan 2008; status: completed.
02
Drugs
A-dmDT390-bisFv(UCHT1)
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00611208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00611208.